Phathom Pharmaceuticals, Inc.
PHAT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $297 | $381 | $155 | $183 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $39 | $2 | $0 | $0 |
| Inventory | $3 | $1 | $0 | $0 |
| Other Curr. Assets | $21 | $13 | $5 | $3 |
| Total Curr. Assets | $360 | $397 | $161 | $187 |
| Property Plant & Equip (Net) | $2 | $4 | $3 | $3 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $3 | $0 | $1 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $13 | $13 | $0 | $0 |
| Total NC Assets | $18 | $16 | $4 | $3 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $378 | $414 | $165 | $189 |
| Liabilities | – | – | – | – |
| Payables | $11 | $13 | $10 | $5 |
| Short-Term Debt | $20 | $1 | $1 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $55 | $25 | $16 | $13 |
| Total Curr. Liab. | $86 | $39 | $26 | $19 |
| LT Debt | $535 | $138 | $96 | $91 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $12 | $310 | $117 | $8 |
| Total NC Liab. | $546 | $448 | $213 | $98 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $1 | $1 | $2 | $2 |
| Total Liabilities | $632 | $487 | $240 | $117 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,263 | -$929 | -$727 | -$529 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $1,009 | $856 | $652 | $602 |
| Total Equity | -$254 | -$73 | -$75 | $72 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $378 | $414 | $165 | $189 |
| Net Debt | $258 | -$242 | -$58 | -$92 |